MoonLake Immunotherapeutics (NASDAQ:MLTX) Earns “Outperform” Rating from Royal Bank of Canada
MoonLake Immunotherapeutics (NASDAQ:MLTX – Get Free Report)‘s stock had its “outperform” rating reiterated by equities researchers at Royal Bank of Canada in a research report issued to clients and investors on Tuesday,Benzinga reports. They presently have a $67.00 price objective on the stock. Royal Bank of Canada’s target price points to a potential upside of […]
MoonLake Immunotherapeutics (NASDAQ:MLTX – Get Free Report)‘s stock had its “outperform” rating reiterated by equities researchers at Royal Bank of Canada in a research report issued to clients and investors on Tuesday,Benzinga reports. They presently have a $67.00 price objective on the stock. Royal Bank of Canada’s target price points to a potential upside of […]
